First Three Children to Commence Treatment With Ryoncil®

Core Insights - Mesoblast has entered into the Medicaid National Drug Rebate Agreement (NDRA) with the U.S. Centers for Medicare & Medicaid Services (CMS) for Ryoncil, enabling coverage for approximately 40% of U.S. children with steroid-refractory acute graft versus host disease (SR-aGvHD) [1][3] - Ryoncil is the first FDA-approved mesenchymal stromal cell (MSC) therapy for pediatric patients aged 2 months and older, with treatment commencing for the first three children this week [2][5] - The recommended treatment course for Ryoncil involves administering 2×10 MSC/kg body weight via intravenous infusion twice per week for four consecutive weeks [2] Company Overview - Mesoblast is a global leader in developing allogeneic cellular medicines for severe inflammatory conditions, utilizing proprietary mesenchymal lineage cell therapy technology [4][6] - The company has a strong intellectual property portfolio with over 1,000 granted patents or applications, providing commercial protection expected to extend through at least 2041 in major markets [7] - Mesoblast is also developing additional therapies for other indications, including adult SR-aGvHD and biologic-resistant inflammatory bowel disease, as well as rexlemestrocel-L for heart failure and chronic low back pain [6]